SCHEMBL4707754

SCHEMBL4707754

Fc1ccc2c(c1)Sc1cc(F)c(F)cc1N2

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOX1 Q9Y5S8 12/20 0.68
SNCA P37840 7/20 0.43
MAPT P10636 4/20 0.43
GAA P10253 3/20 0.43
MAPK1 P28482 2/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
TDP1 Q9NUW8 2/20 0.39
BCHE P06276 2/20 0.39
ACHE P22303 2/20 0.39
CYP1A2 P05177 2/20 0.39
POLB P06746 1/20 0.39
CYP3A4 P08684 1/20 0.39
ADORA3 P0DMS8 1/20 0.39
ALOX15 P16050 1/20 0.39
ALOX12 P18054 1/20 0.39
MAOA P21397 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL342918 0.90 NOX1 (0.81) NOX1SNCAMAPTGAAMAPK1
SCHEMBL6334859 0.89 NOX1 (0.58) NOX1SNCAMAPTGAAMAPK1
SCHEMBL4705873 0.85 NOX1 (0.45) NOX1SNCAMAPTGAAMAPK1
SCHEMBL27861117 0.81 NOX1 (0.68) NOX1SNCAMAPTGAAMAPK1
SCHEMBL11375009 0.76 NOX1 (0.69) NOX1SNCAMAPTGAAMAPK1
SCHEMBL11580815 0.73 NOX1 (0.79) NOX1SNCAMAPTGAAMAPK1
SCHEMBL11034215 0.71 NOX1 (0.54) NOX1SNCAMAPTGAAMAPK1
SCHEMBL9511403 0.67 NOX1 (0.48) NOX1CYP1A2
SCHEMBL29411773 0.67 NOX1 (0.48) NOX1CYP1A2
SCHEMBL4924610 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1765797-A4 PHENOTHIAZINE DERIVATIVES AND THEIR METHOD OF USE UNIV KANSAS CT FOR RES INC (US) 2008-02-06 EP claimed
EP-1765797-A1 PHENOTHIAZINE DERIVATIVES AND THEIR METHOD OF USE University of Kansas Center for Research, Inc. (US) 2007-03-28 EP claimed
WO-2006002441-A1 PHENOTHIAZINE DERIVATIVES AND THEIR METHOD OF USE UNIVERSITY OF KANSAS (US) 2006-01-05 WO claimed
US-20050288279-A1 Phenothiazine derivatives and their method of use KANSAS MEDICAL CENTER, UNIVERSITY OF 2005-12-29 US claimed
EP-1765797-A4 PHENOTHIAZINE DERIVATIVES AND THEIR METHOD OF USE UNIV KANSAS CT FOR RES INC (US) 2008-02-06 EP disclosed
EP-1765797-A1 PHENOTHIAZINE DERIVATIVES AND THEIR METHOD OF USE University of Kansas Center for Research, Inc. (US) 2007-03-28 EP disclosed
WO-2006002441-A1 PHENOTHIAZINE DERIVATIVES AND THEIR METHOD OF USE UNIVERSITY OF KANSAS (US) 2006-01-05 WO disclosed
US-20050288279-A1 Phenothiazine derivatives and their method of use KANSAS MEDICAL CENTER, UNIVERSITY OF 2005-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288279-A1 Phenothiazine derivatives and their method of use SHBG, GPR119, BRDT NOX1 3177/4885SNCA 4293/4885MAPT 2192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.